JRCT ID: jRCT2072230083
Registered date:07/11/2023
Safety confirmation study with dMD-003
Basic Information
Recruitment status | Recruiting |
---|---|
Health condition(s) or Problem(s) studied | Uterine leiomyoma |
Date of first enrollment | 12/04/2024 |
Target sample size | 30 |
Countries of recruitment | |
Study type | Interventional |
Intervention(s) | The study device (dMD-003) is applied to the injury site of the uterus immediately before wound closure in uterine myomectomy. |
Outcome(s)
Primary Outcome | Incidence of adverse events up to 12 weeks after surgery. |
---|---|
Secondary Outcome |
Key inclusion & exclusion criteria
Age minimum | >= 20age old |
---|---|
Age maximum | Not applicable |
Gender | Female |
Include criteria | (1) Patients scheduled to undergo laparoscopic, laparoscopy-assisted, or open uterine myomectomy. Other criteria. |
Exclude criteria | (1) Patients who have undergone surgery in the abdominal or pelvic cavity (excluding surgery for appendicitis). (2) Patients with concurrent active pelvic inflammatory disease or peritonitis. (3) Patients suspected of having moderate (stage III) or severe endometriosis according to the r-ASRM classification. Other criteria. |
Related Information
Primary Sponsor | Aihara Fumiaki |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | |
Secondary ID(s) |
Contact
Public contact | |
Name | Public relations |
Address | 7, Yotsuya 1-chome, Shinjuku-ku, Tokyo Tokyo Japan 160-8515 |
Telephone | +81-3-3225-6303 |
webmaster@mochida.co.jp | |
Affiliation | Mochida Pharmaceutical Co., Ltd. |
Scientific contact | |
Name | Fumiaki Aihara |
Address | 7, Yotsuya 1-chome, Shinjuku-ku, Tokyo Tokyo Japan 160-8515 |
Telephone | +81-3-3225-6306 |
dmd003.mdbd@mochida.co.jp | |
Affiliation | Mochida Pharmaceutical Co., Ltd. |